Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

PartnershipSP001Positive

AI Analysis

Summary

Spero Therapeutics and Innovent Biologics announced an exclusive license agreement for SP001 (IBI355), a Phase 2-ready third-generation anti-CD40L antibody. The deal represents a significant partnership for advancing the therapeutic candidate.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Exclusive license agreement for SP001 (IBI355), a Phase 2-ready third-generation anti-CD40L antibody

Importance:7/10

Sentiment:

0.60

licensingpartnershipantibodyanti-CD40LPhase 2

Related Companies

$IVBXF

Read the original article

Published by yahoo_finance on July 14, 2026 10:00 AM

Read Original